Gilead secures FDA authorisation for remdesivir to treat Covid-19
The FD authorisation will enable the use of remdesivir to treat hospitalised patients with severe Covid-19 disease in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 May 20
The FD authorisation will enable the use of remdesivir to treat hospitalised patients with severe Covid-19 disease in…
01 May 20
The collaboration between AstraZeneca and Oxford University will enable global development, manufacturing and distribution of the new COVID-19…
30 Apr 20
Zejula is an oral monotherapy used as treatment for women regardless of BRCA mutational status, addressing a high…
30 Apr 20
Supernus will acquire APOKYN, MYOBLOC, and XADAGO, along with Apomorphine Infusion Pump, which is currently under late-stage development
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Apr 20
FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants…
29 Apr 20
Cosentyx is indicated for patients with non-radiographic axial spondyloarthritis (nr-axSpA), a part of the axial spondyloarthritis (axSpA) disease…
28 Apr 20
Moderna’s new mRNA-1273 is an mRNA vaccine that works against SARS-CoV-2 encoding for a prefusion stabilized form of…
28 Apr 20
Regeneron and Sanofi have amended the clinical trial to continue enrolling only critical patients to receive Kevzara 400mg…
Analysts are torn on the potential of remdesivir as a Covid-19 vaccine after Gilead Sciences halted a trial…
27 Apr 20
Lynparza has been granted priority review by the US Food and Drug Administration for patients with HRRm mCRPC